ISSN:0277-0008    

DOI:10.1002/j.1875-9114.1996.tb03663.x

出版商:Blackwell Publishing Ltd    

年代:1996

数据来源: WILEY

摘要:

The number of thrombolytic drugs for the management of acute myocardial infarction is rapidly expanding. New agents, some of which are biochemically modified versions of currently available thrombolytics, will soon arrive in the marketplace. The pharmacologic differences of the new drugs are the basis for clinical differences such as enhanced clot lysis and prolonged elimination half‐life. Ultimately, these features may result in improved infarct artery patency and patient surviva

ISSN:0277-0008    

DOI:10.1002/j.1875-9114.1996.tb03664.x

出版商:Blackwell Publishing Ltd    

年代:1996

数据来源: WILEY

摘要:

Clinical trials continue to evaluate the pharmacologic management of myocardial infarction for benefits in mortality, degree of infarct artery patency, and frequency of reocclusion. The discovery of thrombus formation in the development of the myocardial infarction renewed interest in thrombolytic therapy. In appropriate candidates, timely administration of thrombolytics after myocardial infarction restores coronary artery patency, reduces myocardial ischemic damage, and improves left ventricular function. Adjunct therapy for thrombolysis typically includes aspirin, heparin, β‐blockers, nitroglycerin, and angiotensin‐converting enzyme inhibitors, if not contraindicated. To reduce cardiac risk, postthrombolysis management generally includes aspirin, β‐blockers, and angiotensin‐converting enzyme inhibitors together with efforts to reduce known cardiovascular ris

ISSN:0277-0008    

DOI:10.1002/j.1875-9114.1996.tb03665.x

出版商:Blackwell Publishing Ltd    

年代:1996

数据来源: WILEY

摘要:

Although the ability of a thrombolytic agent to lyse a clot has been recognized for over 50 years, it was not until recently that this form of therapy was used to treat acute myocardial infarction. The need for rapid diagnosis and timely treatment to provide optimum outcomes and prognosis is now well established. Numerous clinical trials continue to examine alternative therapeutic regimens as well as the efficacy and safety of new agents to improve short‐ and long‐term outcomes further. Reteplase is a new recombinant tissue‐type plasminogen activator with potential advantages over currently available a

ISSN:0277-0008    

DOI:10.1002/j.1875-9114.1996.tb03666.x

出版商:Blackwell Publishing Ltd    

年代:1996

数据来源: WILEY